exidavnemab vs UB-312
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline
exidavnemab
Developed by BioArctic AB and partners
NCT06671938 · Phase 2 · completed
This is a randomized, double-blind, placebo-controlled trial, but it enrolled only 38 participants split across dose cohorts, its primary endpoint measures adverse-event incidence rather than efficacy, and results have not yet been posted, so no conclusion about benefit can be drawn. Its registered primary outcome on ClinicalTrials.gov is "Number of participants with adverse events (AEs) and serious adverse events (SAEs).". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
UB-312
Developed by Vaxxinity
NCT04075318 · Phase 1 · completed
A randomized, quadruple-blind, placebo-controlled phase 1 study of the UB-312 vaccine in 70 participants. The design is sound but small, and its primary measures were safety and immunogenicity: anti-alpha-synuclein antibody responses were reported in blood while cerebrospinal-fluid responses were only partial, with no statistical analyses posted, so the primary outcomes read as mixed.
Reported efficacy
Frequency of Adverse Events (44 weeks); Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in Blood (44 weeks); Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in CSF (44 weeks): Frequency of Adverse Events (44 weeks): Part A: UB-312 40 mcg 22 TEAEs | Part A: UB-312 100 mcg 31 TEAEs | Part A: UB-312 40/300 mcg 25 TEAEs | Part A: UB-312 300 mcg 31 TEAEs | Part A: UB-312 40/1000 mcg 24 TEAEs | Part A: UB-312 1000 mcg 17 TEAEs | Part A: UB-312 2000 mcg 18 TEAEs | Part A: Placebo 25 TEAEs | Part B: UB-312 300/100 mcg 59 TEAEs | Part B: UB-312 300 mcg 42 TEAEs | Part B: Placebo 20 TEAEs (mixed)
Result source: NCT04075318
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | exidavnemab | UB-312 |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | —Not reported | —Not reported |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- exidavnemab
- —Not reported
- UB-312
- —Not reported
ON time without troublesome dyskinesia, change
- exidavnemab
- —Not reported
- UB-312
- —Not reported
UPDRS Part III, change
- exidavnemab
- —Not reported
- UB-312
- —Not reported
MDS-UPDRS Part II, change
- exidavnemab
- —Not reported
- UB-312
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
exidavnemab: no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. exidavnemab: 0 of 4 rows · UB-312: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | UB-312 |
|---|---|
| Dropout rate | 100%2000 mcga NCT04075318 · Phase 1 · monotherapy show 8 more results100%1000 mcg NCT04075318 · Phase 1 · monotherapy 100%40/1000 mcg NCT04075318 · Phase 1 · monotherapy 0%300 mcg NCT04075318 · Phase 1 · monotherapy 16.7%40/300 mcg NCT04075318 · Phase 1 · monotherapy 0%300 mcg NCT04075318 · Phase 1 · monotherapy 14.3%300/100 mcg NCT04075318 · Phase 1 · monotherapy 0%100 mcg NCT04075318 · Phase 1 · monotherapy 0%40 mcg NCT04075318 · Phase 1 · monotherapy |
| Discontinued due to AEs | —2000 mcga NCT04075318 · Phase 1 · monotherapy show 8 more results—1000 mcg NCT04075318 · Phase 1 · monotherapy —40/1000 mcg NCT04075318 · Phase 1 · monotherapy —300 mcg NCT04075318 · Phase 1 · monotherapy —40/300 mcg NCT04075318 · Phase 1 · monotherapy —300 mcg NCT04075318 · Phase 1 · monotherapy —300/100 mcg NCT04075318 · Phase 1 · monotherapy —100 mcg NCT04075318 · Phase 1 · monotherapy —40 mcg NCT04075318 · Phase 1 · monotherapy |
| Serious AEs | 0%2000 mcga NCT04075318 · Phase 1 · monotherapy show 8 more results0%1000 mcg NCT04075318 · Phase 1 · monotherapy 0%40/1000 mcg NCT04075318 · Phase 1 · monotherapy 0%300 mcg NCT04075318 · Phase 1 · monotherapy 0%40/300 mcg NCT04075318 · Phase 1 · monotherapy 0%300 mcg NCT04075318 · Phase 1 · monotherapy 42.9%300/100 mcg NCT04075318 · Phase 1 · monotherapy 0%100 mcg NCT04075318 · Phase 1 · monotherapy 0%40 mcg NCT04075318 · Phase 1 · monotherapy |
| Most frequent reported AEs | 2000 mcga general disorders and administration site conditions 83.3% (placebo 62.5%) nervous system disorders 66.7% (placebo 62.5%) infections and infestations 50% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy show 8 more results1000 mcg general disorders and administration site conditions 100% (placebo 62.5%) infections and infestations 33.3% (placebo 62.5%) nervous system disorders 33.3% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 40/1000 mcg general disorders and administration site conditions 66.7% (placebo 62.5%) infections and infestations 50% (placebo 62.5%) nervous system disorders 50% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 300 mcg general disorders and administration site conditions 100% (placebo 62.5%) muscoloskeletal and connective tissue disorders 66.7% (placebo 25%) nervous system disorders 50% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 40/300 mcg general disorders and administration site conditions 66.7% (placebo 62.5%) infections and infestations 50% (placebo 62.5%) nervous system disorders 50% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 300 mcg nervous system disorders 100% (placebo 62.5%) infections and infestations 71.4% (placebo 62.5%) vascular disorders 42.9% (placebo 0%) NCT04075318 · Phase 1 · monotherapy 300/100 mcg injury, poisoning and procedural complications 85.7% (placebo 0%) nervous system disorders 85.7% (placebo 62.5%) general disorders and administration site conditions 57.1% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 100 mcg general disorders and administration site conditions 66.7% (placebo 62.5%) infections and infestations 66.7% (placebo 62.5%) nervous system disorders 50% (placebo 62.5%) NCT04075318 · Phase 1 · monotherapy 40 mcg general disorders and administration site conditions 83.3% (placebo 62.5%) nervous system disorders 66.7% (placebo 62.5%) muscoloskeletal and connective tissue disorders 33.3% (placebo 25%) NCT04075318 · Phase 1 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: exidavnemab's landscape · UB-312's landscape